Payment overview · 2025
General Payments
$591.64
46 reported records · 7 companies
Healthcare provider profile · identity verified
Lee Saindon, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREER, SC · NPI 1821102575
Verified facts
What the public records show
CMS Open Payments records show Lee Saindon, MD received $591.64 in general payments during 2025 across 46 reported records.
Novo Nordisk Inc accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $179.61 | 30.4% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $149.27 | 25.2% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $146.18 | 24.7% | 14 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$51.48 | 8.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.62 | 5.2% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.60 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.88 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $591.64 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $129.83 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $102.37 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $84.48 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $84.00 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.18 | 4 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $51.48 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.78 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $46.90 | 2 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $36.58 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.62 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $12.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 329 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 323 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 78 |
| Lorazepam | Lorazepam | 273 | 37 |
| Omeprazole | Omeprazole | 226 | 56 |
| Atorvastatin Calcium | Atorvastatin Calcium | 224 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 202 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 201 | 23 |
| Gabapentin | Gabapentin | 183 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 44 |
| Metformin Hcl | Metformin Hcl | 171 | 41 |
| Alprazolam | Alprazolam | 164 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 39 |
| Trazodone Hcl | Trazodone Hcl | 139 | 31 |
| Simvastatin | Simvastatin | 137 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 123 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 31 |
| Tramadol Hcl | Tramadol Hcl | 120 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 38 |
| Meloxicam | Meloxicam | 105 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 24 |
| Sertraline Hcl | Sertraline Hcl | 103 | 24 |
| Losartan Potassium | Losartan Potassium | 101 | 22 |
| Furosemide | Furosemide | 99 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 31 |
| Cephalexin | Cephalexin | 87 | 65 |
| Montelukast Sodium | Montelukast Sodium | 85 | 23 |
| Allopurinol | Allopurinol | 83 | 21 |
| Prednisone | Prednisone | 74 | 46 |
| Temazepam | Temazepam | 74 | suppressed |
| Ozempic | Semaglutide | 71 | 13 |
| Atenolol | Atenolol | 70 | 16 |
| Glipizide | Glipizide | 69 | 13 |
| Metformin Hcl Er | Metformin Hcl | 68 | 15 |
| Celecoxib | Celecoxib | 65 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 18 |
| Eliquis | Apixaban | 64 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 26 |
| Methylprednisolone | Methylprednisolone | 63 | 50 |
| Synthroid | Levothyroxine Sodium | 63 | suppressed |
| Bupropion Xl | Bupropion Hcl | 62 | 12 |
| Clonazepam | Clonazepam | 61 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 14 |
| Carvedilol | Carvedilol | 53 | 13 |
| Estradiol | Estradiol | 53 | 11 |
| Glipizide Er | Glipizide | 53 | 12 |
| Potassium Chloride | Potassium Chloride | 53 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | suppressed |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Ibuprofen | Ibuprofen | 42 | 12 |
| Azithromycin | Azithromycin | 40 | 31 |
| Promethazine Hcl | Promethazine Hcl | 39 | 11 |
| Diazepam | Diazepam | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 16 |
| Amoxicillin | Amoxicillin | 35 | 19 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 28 |
| Famotidine | Famotidine | 32 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 16 |
| Meclizine Hcl | Meclizine Hcl | 30 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 20 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 19 |
| Lovastatin | Lovastatin | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Np Thyroid | Thyroid,pork | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $591.64 · 46 records | Novo Nordisk Inc | AIRSUPRA, FANAPT, HETLIOZ, INTELLIS ADAPTIVESTIM, JARDIANCE, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, Saxenda, Tresiba, UBRELVY, VRAYLAR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error